Vimarsana
Biggest News Aggregation in the World

Oral Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oral Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oral Presentation Today - Breaking & Trending Today

Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical Trial: Positive Trend Observed ... - Vimarsana News

Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical Trial: Positive Trend Observed ...

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0

Source: menafn.com
Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress - Vimarsana News

Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress

Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress 28 May 2024, Glasgow, Scotland – Mironid…

Antengene To Present One Oral and Four Abstracts at ASCO 2024 - Vimarsana News

Antengene To Present One Oral and Four Abstracts at ASCO 2024

/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated...

Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference - Vimarsana News

Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference

/PRNewswire/ -- Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult...

AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - Form 6-K - Vimarsana News

AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - Form 6-K

A6269o FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...